Dosage And Administration Section
DOSAGE AND ADMINISTRATION
Adults
Two tablets per day; one in the morning and one in the evening.
Orphenadrine Citrate Tablet, Extended Release
FDA Label NDC 80425-0117
Full FDA labeling including Indications, Dosage, Usage, and Precautions
Structured Product Label
The following Structured Product Label (SPL) was submitted to the FDA by Advanced Rx Pharmacy Of Tennessee, Llc for the product Orphenadrine Citrate (NDC 80425-0117). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding dosage and administration section, indications and usage section, principal display panel, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Label Section Quick Index
Indications And Usage Section
INDICATIONS AND USAGE
Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.
* Please review the disclaimer below.
